Collegium Pharmaceutical Surges 12% on ADHD Drug Growth, Ups Guidance

Key Facts

1Collegium Pharmaceutical stock gained 12% in three months driven by strong growth of Jornay PM and the Azstarys acquisition, boosting 2026 guidance.

Amid rising demand for ADHD treatments, Collegium Pharmaceutical stock gained 12% over three months, according to reports. The rally was driven by strong growth of Jornay PM and the acquisition of Azstarys, which prompted the company to raise its 2026 revenue guidance.

The ADHD drug market continues to expand, benefiting companies with differentiated products. Collegium's strategy of acquiring complementary drugs appears to be paying off, as both Jornay PM and Azstarys contributed to revenue growth. This performance comes amid increasing competition from peers such as Supernus and Takeda.

COLL closed at $36.20 on June 30, 2026, trading within a range of $35.17 to $36.30. Investors await upcoming quarterly reports to assess progress toward the raised 2026 guidance. Regulatory developments or new competition could also influence the stock's trajectory.